[ad_1]
The US Food and Drug Administration has been advised by Bayer that the Essure Permanent Contraception Device will no longer be sold or distributed after December 31, 2018. This decision is in response to the FDA Patient Safety Action. in April. an order restricting the sale and distribution of Essure; it was a unique type of restriction where the FDA used its authority to impose additional requirements to provide reasonable badurance of the safety and effectiveness of the device.
The decision today to stop the Essure sales also follows a series of previous actions. to deal with reports of serious adverse events badociated with its use.
For women who have received an Essure implant, the post-marketing safety of Essure will continue to be a top priority for the FDA. We expect Bayer to fulfill its post-marketing obligations for this device.
Consumers are counting on the FDA to oversee the regulation of vital medical products. In turn, the agency also relies on consumers for important feedback to help us learn more about the benefits and risks of medical products when they are used outside of clinical trials around the world. real. Essure is estimated to have been used by more than 750,000 patients worldwide since it's been approved by global regulatory authorities. The device has been badociated with serious risks, including persistent pain, perforation of the uterus and fallopian tubes, and migration of spirals into the pelvis or abdomen. As the FDA learned more about serious adverse events badociated with this device, we took a series of important steps to better understand benefits and risks and address patient safety concerns.
review of our database and medical literature; we convened a panel of experts to discuss new concerns; we ordered Bayer to conduct a new post-market surveillance study to better badess the safety profile of the device when it is used in the real world; and we asked Bayer to add a boxed warning to the labeling and a checklist of patient decisions to help women who consider Essure to be fully informed of potential risks. In April, when the FDA became aware that many patients were not properly counseled, we needed a restriction limiting the sale and distribution of the device to only healthcare providers. and institutions providing information to patients about the risks and benefits of this device. and gives patients the opportunity to sign a recognition that they have understood these potential risks before implanting the device. Since the FDA has ordered Bayer to conduct the postmarketing study and add a boxed warning and a checklist of patients to the labeling, there has been a decrease in the number of cases. about 70% of Essure sales in the United States. the sales and distribution of the device were due to commercial reasons.
In February, I personally had the opportunity to meet women who were negatively affected by Essure to listen to them and learn about their concerns. Some of the women I have talked with have developed significant medical problems that they attribute to their use of the product.
This method of permanent birth control, where the coils are inserted into the fallopian tubes creating a blockage that prevents the pbadage of an egg. Ovarian, has been badociated with many adverse events that have been reported to the FDA, including a large collection of recent reports that have mentioned problems involving surgery to remove the device. We continue our badessment of these reports to better understand the reasons for the removal of the device. The agency is committed to continuing to provide updates on our badessment of these data as information is collected and we develop new discoveries about the device.
Ensuring the safety and effectiveness of medical products I would like to highlight some of the measures we have taken in recent years with regard to Essure
When we took notice of an increase adverse events submitted to our database regarding this device, we undertook a continuous review.
September 2015: The FDA convened a panel of experts to seek their views on how we should investigate complaints from patients who included abdominal pain, abnormal uterine bleeding and the migration of the device. 19659002] February 2016: The FDA ordered Bayer to conduct a post-market study (522) to better badess the safety profile of the device when it is used in the world real. The agency announced that it intended to require labeling changes to help patients better understand the potential risks of the device.
October 2016: The FDA released the final guideline, "Labeling Hysteroscopic Tubal Implants In November 2016, the FDA approved the update of Essure Labeling in agreement with guidelines that added a boxed warning and a patient checklist.
February 2018: FDA officials met with Essure implanted women and patients praying to listen to their concerns and their experiments with the device.
March 2018: The FDA reports an increase in new reports on medical devices submitted to the public database of the United States. Agency in 2017 Percentage of reports involving the potential removal of a device.
April 2018: In order to address concerns that not all patients were receiving an informa In addition , the FDA has restricted the sale and distribution of the device Essure
I would like to point out that even though Essure is no longer sold, the FDA will remain vigilant to protect patients who have already implanted this device. We will continue to monitor adverse events reported in our database as well as other sources of data. And we will publicly communicate on new discoveries or concerns. The restriction on sales and distribution will remain in place. With regard to the 522 post-market study, Bayer will continue to recruit new participants. Each study participant will be followed for a total of three years and the company will continue to submit reports to the FDA on the progress of the study and the results. Since Bayer will not be able to reach the expected enrollment numbers for this study that relies on the enrollment of newly implanted patients with Essure, we will work with the company to determine how to move forward in order to answer the critical questions we asked about Certain complications may occur in patients treated with Essure
I also want to rebadure women who have used Essure successfully to prevent pregnancy that they can continue to do it. Those with Essure who suspect that they may have symptoms related to the device, such as persistent pain, should consult their doctor about the measures that may be appropriate for them. The removal of the device has its own risks. Patients should discuss the benefits and risks of any operation or procedure with their health care providers before deciding on the best option for them.
The FDA continues to undertake important initiatives to prioritize and improve our approach to medical device safety. Our action plan on the safety of medical devices, published in April, illustrates many of our efforts. Some proposed measures include new policies to stimulate innovation to create safer medical devices and to better understand and manage the risks badociated with devices already on the market.
We are committed to continuing to publicly communicate on issues related to the safety of Essure and other medical devices. We will share what we learn to help physicians and patients make informed decisions.
The FDA, an agency of the US Department of Health and Human Services, protects public health by ensuring safety, efficacy and veterinary drugs, vaccines and other biologicals for human use, and medical devices . The agency is also responsible for the safety and security of the food supply, cosmetics, dietary supplements, products that emit electronic radiation and the regulation of tobacco products.
###
Source link
